BRPI0718052A2 - Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas - Google Patents
Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradasInfo
- Publication number
- BRPI0718052A2 BRPI0718052A2 BRPI0718052-7A BRPI0718052A BRPI0718052A2 BR PI0718052 A2 BRPI0718052 A2 BR PI0718052A2 BR PI0718052 A BRPI0718052 A BR PI0718052A BR PI0718052 A2 BRPI0718052 A2 BR PI0718052A2
- Authority
- BR
- Brazil
- Prior art keywords
- diphenylazotidinone
- piperazine
- substituted
- sulfonic acid
- pharmacological properties
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006051655 | 2006-11-02 | ||
PCT/EP2007/009018 WO2008052658A1 (de) | 2006-11-02 | 2007-10-18 | Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0718052A2 true BRPI0718052A2 (pt) | 2015-06-16 |
Family
ID=38875004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0718052-7A BRPI0718052A2 (pt) | 2006-11-02 | 2007-10-18 | Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas |
Country Status (20)
Country | Link |
---|---|
US (1) | US20090264402A1 (pt) |
EP (1) | EP2091915A1 (pt) |
JP (1) | JP2010508313A (pt) |
KR (1) | KR20090091120A (pt) |
CN (1) | CN101535249A (pt) |
AR (1) | AR063747A1 (pt) |
AU (1) | AU2007315327A1 (pt) |
BR (1) | BRPI0718052A2 (pt) |
CA (1) | CA2668094A1 (pt) |
CL (1) | CL2007003175A1 (pt) |
CO (1) | CO6160306A2 (pt) |
IL (1) | IL198427A0 (pt) |
MA (1) | MA30819B1 (pt) |
MX (1) | MX2009003823A (pt) |
NO (1) | NO20091746L (pt) |
RU (1) | RU2009120679A (pt) |
TW (1) | TW200826941A (pt) |
UY (1) | UY30682A1 (pt) |
WO (1) | WO2008052658A1 (pt) |
ZA (1) | ZA200901981B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20100286112A1 (en) | 2007-09-10 | 2010-11-11 | Oscar Barba | Compounds for the treatment of metabolic disorders |
CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
RS59411B1 (sr) | 2013-03-13 | 2019-11-29 | Forma Therapeutics Inc | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodna jedinjenja kao inhibitori sintaze masnih kiselina (fasn) za lečenje kancera |
CN104193731B (zh) * | 2014-08-27 | 2017-03-15 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
CN104513187B (zh) * | 2015-01-09 | 2017-05-31 | 安润医药科技(苏州)有限公司 | 依折麦布及其中间体的合成方法 |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10227506A1 (de) * | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
-
2007
- 2007-10-18 EP EP07819086A patent/EP2091915A1/de not_active Withdrawn
- 2007-10-18 CN CNA2007800406687A patent/CN101535249A/zh active Pending
- 2007-10-18 CA CA002668094A patent/CA2668094A1/en not_active Abandoned
- 2007-10-18 RU RU2009120679/04A patent/RU2009120679A/ru not_active Application Discontinuation
- 2007-10-18 AU AU2007315327A patent/AU2007315327A1/en not_active Abandoned
- 2007-10-18 JP JP2009535005A patent/JP2010508313A/ja not_active Withdrawn
- 2007-10-18 BR BRPI0718052-7A patent/BRPI0718052A2/pt not_active IP Right Cessation
- 2007-10-18 KR KR1020097009147A patent/KR20090091120A/ko not_active Application Discontinuation
- 2007-10-18 MX MX2009003823A patent/MX2009003823A/es not_active Application Discontinuation
- 2007-10-18 WO PCT/EP2007/009018 patent/WO2008052658A1/de active Application Filing
- 2007-10-31 UY UY30682A patent/UY30682A1/es unknown
- 2007-10-31 AR ARP070104833A patent/AR063747A1/es unknown
- 2007-10-31 TW TW096140895A patent/TW200826941A/zh unknown
- 2007-11-02 CL CL200703175A patent/CL2007003175A1/es unknown
-
2009
- 2009-03-20 ZA ZA200901981A patent/ZA200901981B/xx unknown
- 2009-04-17 CO CO09038965A patent/CO6160306A2/es unknown
- 2009-04-27 IL IL198427A patent/IL198427A0/en unknown
- 2009-04-29 MA MA31829A patent/MA30819B1/fr unknown
- 2009-04-30 US US12/432,997 patent/US20090264402A1/en not_active Abandoned
- 2009-05-04 NO NO20091746A patent/NO20091746L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA30819B1 (fr) | 2009-10-01 |
CO6160306A2 (es) | 2010-05-20 |
CN101535249A (zh) | 2009-09-16 |
KR20090091120A (ko) | 2009-08-26 |
NO20091746L (no) | 2009-07-21 |
MX2009003823A (es) | 2009-05-11 |
CL2007003175A1 (es) | 2008-05-16 |
AR063747A1 (es) | 2009-02-18 |
TW200826941A (en) | 2008-07-01 |
EP2091915A1 (de) | 2009-08-26 |
RU2009120679A (ru) | 2010-12-10 |
WO2008052658A1 (de) | 2008-05-08 |
UY30682A1 (es) | 2008-07-03 |
AU2007315327A1 (en) | 2008-05-08 |
IL198427A0 (en) | 2010-02-17 |
US20090264402A1 (en) | 2009-10-22 |
ZA200901981B (en) | 2010-03-31 |
CA2668094A1 (en) | 2008-05-08 |
JP2010508313A (ja) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0718052A2 (pt) | Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas | |
BRPI0715617A2 (pt) | Derivados do ácido fenoxifenilacético 4-substituído | |
DK2126093T3 (da) | Forbedring af proteinfremstilling | |
BRPI0810472A2 (pt) | Métodos relacionados à glicosilação da superfície celular | |
DE102007063274B8 (de) | Mikroskop | |
NO20085127L (no) | Leptomycinderivater | |
DE602007008020D1 (de) | Polarisationsumwandlung | |
BRPI0913934A2 (pt) | compostos tendo propriedades antivirais | |
ATE510923T1 (de) | Nukleinsäure | |
FI7098U1 (fi) | Kaidejärjestelmä | |
DK2021792T3 (da) | Opløste protein-artritmarkører | |
FI20065446A0 (fi) | Muodostusosa | |
CR10759A (es) | Farmaco combinado | |
DE602007001914D1 (de) | Schalter | |
DE602007008903D1 (de) | Auspuffrohrstruktur | |
DK2220036T3 (da) | Dioxoanthracensulfonatderivater | |
BRPI0815595A2 (pt) | Composição antifúngica | |
DK2064356T3 (da) | Sulfatproces | |
DE502007003774D1 (de) | Werkzeugaufnahme | |
DE602007010931D1 (de) | Säurefarbstoffe | |
DK1826334T3 (da) | Nødoverløb | |
FR2897882B1 (fr) | Structure de batiment | |
DE602007001604D1 (de) | Säurefarbstoffe | |
DK1873317T3 (da) | Fladt afløb | |
DE502006004267D1 (de) | Umschaltventil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |